ESSA Pharma Inc. Stock News

EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of convincing data yet.

The stock has pulled back from the 2x pop after the recent data of EPI-7386+Xtandi in post-chemotherapy metastatic castration-resistant prostate cancer, mCRPC. The efficacy of the EPI-7386+Xtandi comb

Check these strategies out for buying penny stocks right no The post 3 Beginner Penny Stocks Trading Mistakes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these strategies for making money with penny stocks The post Top Strategies for Making Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

ESSA Pharma (NASDAQ: EPIX ) stock is flying higher on Wednesday following the release of data from a Phase 1/2 study of EPI-7386. EPI-7386 is a drug in development for the treatment of metastatic cast

Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90% since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness

Insiders love these 3 penny stocks in July 2022 The post 3 Best Penny Stocks To Buy According To Insiders; 1 Bet Over $1.7 Million appeared first on Penny Stocks to Buy, Picks, News and Information |

South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the…

ESSA Pharma (EPIX) said the first patient was dosed in a phase 1/2 study of its lead product candidate EPI-7386, in combination with Astellas Pharma''s (ALPMF) and Pfizer''s

ESSA Pharma Inc. (NASDAQ: EPIX ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA''s lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.''s ("Astellas") and Pfizer Inc.''s ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer ("mCRPC"). "The initiation of this combination trial with Astellas is a watershed moment for ESSA as we investigate the potential clinical benefit of inhibiting the androgen receptor through two independent pathways in the Full story available on Benzinga.com

Essa Pharma Inc (EPIX) shares closed this week 25.9% lower than it did at the end of last week. The stock is currently down 34.4% year-to-date, down 41.1% over the past 12 months, and up 337.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $12.74 and as low as $8.27 this week.Shares closed 74.1% below its 52-week high and 25.6% above its 52-week low.Trading volume this week was 24.8% higher than the 10-day average and 126.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 5618.5% The company's stock price performance over the past 12 months lags the peer average by 155.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) rose 6.4% on Monday . The stock traded as high as $12.01 and last traded at $12.01. Approximately 3,086 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 373,471 shares. The stock had previously closed at $11.29. The firms 50 day []

Wall Street brokerages expect ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) to announce earnings per share (EPS) of ($0.25) for the current quarter, Zacks reports. Zero analysts have provided estimates for ESSA Pharmas earnings, with the lowest EPS estimate coming in at ($0.31) and the highest estimate coming in at ($0.21). ESSA Pharma posted earnings of ($0.20) []

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 937,100 shares, a drop of 25.0% from the October 31st total of 1,250,000 shares. Currently, 5.6% of the companys shares are short sold. Based on an average daily trading []

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) was the target of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 937,100 shares, a decrease of 25.0% from the October 31st total of 1,250,000 shares. Currently, 5.6% of the shares of the company are short sold. Based []